Canada markets close in 44 minutes

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9001+0.0013 (+0.14%)
As of 3:01PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.8988
Bid0.8901 x 800
Ask0.9010 x 900
Day's Range0.8850 - 0.9200
52 Week Range0.8400 - 3.7900
Avg. Volume819,136
Market Cap91.114M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.5770
Earnings DateNov. 08, 2021 - Nov. 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • GlobeNewswire

    Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses

    NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations include a poster presentation on the long-term wound healing and pain relief data from the Phase 1/2a EB-101 trial at the 2021 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, held virtually

  • GlobeNewswire

    Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality

    NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a consultant, will now serve in a leadership role to further strengthen Abeona’s quality system and oversee all quality functions. “Jon is a proven technical leader with a strong track record of successful quality oversigh

  • GlobeNewswire

    Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings

    Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board Vishwas Seshadri, Ph.D., M.B.A. to become Chief Executive Officer Brendan M. O’Malley, J.D., Ph.D. promoted to General Counsel, Brian Kevany, Ph.D. promoted to Chief Technical Officer, Scott Nogi, M.B.A., Head of Business Operations to expand role and lead operations at Abeona’s Cleveland facility Regulatory veterans in AAV-based gene therapy, Carl Denny and Kate Imhoff, added to team in prepa